Cover Image
Market Research Report
Product code 
676695

Intravenous Immunoglobulin (IVIG) Market by Application and Type: Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Published: | Allied Market Research | 202 Pages | Delivery time: 2-3 business days

Price

Back to Top
Intravenous Immunoglobulin (IVIG) Market by Application and Type: Global Opportunity Analysis and Industry Forecast, 2018 - 2025
Published: February 19, 2019
Allied Market Research
Content info: 202 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

Title:
Intravenous Immunoglobulin (IVIG) Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre syndrome, and Others) and Type (IgG, IgA, IgM, IgE, and IgD): Global Opportunity Analysis and Industry Forecast, 2018 - 2025 .

Intravenous Immunoglobulin Market Overview:

  • The global intravenous immunoglobulin (IGIV) market was valued at $8,995 million in 2017and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.
  • Immunoglobulins (Igs), also referred to as antibodies, are glycoproteins produced by the blood plasma in response to foreign bodies or antigens. They are highly complex entities and are specific in their action. These immunoglobulins are obtained from blood through the process of fractionation and are purified for use in therapeutic and nontherapeutic areas.
  • Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia, & others and rise in adoption of immunoglobulin therapies for the treatment of various autoimmune disorders majorly drive the growth of the IVIG market. Furthermore, increase in approval of IVIG drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and other government agencies is expected to accelerate the growth of the IVIG industry. However, stringent government regulations toward the vigorous use of immunoglobulins, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin intravenously are anticipated to hamper the market growth. On the contrary, significant investment in healthcare sector is expected to provide lucrative opportunities for the market growth in the near future.
  • The global intravenous immunoglobulin (IVIG) market is characterized based on application, type, and region. By application, the market is segmented into hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, Guillaina€"Barre syndrome, and others. Depending on type, it is classified into IgG, IgA, IgM, IgE, and IgD. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits for Intravenous Immunoglobulin Market:

  • The report provides an in-depth analysis of the intravenous immunoglobulin market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in this study.
  • The report provides a detailed quantitative analysis of the industry from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
  • An extensive analysis of the key segments of the industry helps to understand the trends in the intravenous immunoglobulin market globally.
  • Key players and their strategies are provided to understand the competitive outlook of the industry.

Intravenous Immunoglobulin Key Market Segments:

By Application

  • Hypogammaglobulinemia
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Primary Immunodeficiency Disease
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Inflammatory Myopathies
  • Specific Antibody Deficiency
  • Guillaina€"Barre Syndrome
  • Others

By Type

  • IgG
  • IgA
  • IgM
  • IgE
  • IgD

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • France
  • Germany
  • Italy
  • France
  • Austria
  • Russia
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Argentina
  • Turkey
  • Saudi Arabia
  • Rest of LAMEA
  • Key Players Profiled
  • Baxter international Inc.
  • CSL Ltd.
  • Grifols, S.A.
  • Octapharma AG
  • Kedrion Biopharma Inc.
  • LFB Group
  • Biotest AG
  • China Biologics Products, Inc.
  • Takeda Pharmaceuticals
  • Bayer AG

The other players of the intravenous immunoglobulin market included in the value chain analysis (but not profiled in the report) are as follows:

  • Hualan Biological Engineering Inc.
  • Omrix Biopharmaceuticals Ltd.
  • Behring GmbH
  • Shanghai RAAS Blood Products Co., Ltd.
  • Option Care Enterprises, Inc.
  • ADMA Biologics, Inc.
  • BioScrip, Inc.
Product Code: LI_16325

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits for stakeholders
  • 1.3. Key market segments
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Overview of Immunoglobulin
    • 3.2.1. Patented products
    • 3.2.2. Epidemiology and economic burden of chronic conditions
  • 3.3. Key findings
    • 3.3.1. Top Investment Pockets
  • 3.4. Porters five forces analysis
  • 3.5. Value chain analysis
    • 3.5.1. Primary activities
    • 3.5.2. Support activities
  • 3.6. Market share analysis, 2017
  • 3.7. Product scenario in intravenous immunoglobulin market
  • 3.8. Government regulations and reimbursements
    • 3.8.1. U.S.
    • 3.8.2. Europe
    • 3.8.3. France
    • 3.8.4. Germany
    • 3.8.5. Italy
    • 3.8.6. China
    • 3.8.7. Japan
    • 3.8.8. India
  • 3.9. Indications for immunoglobulin
    • 3.9.1. U.S. FDA indications
    • 3.9.2. EMA
  • 3.10. Component analysis of immunoglobulin G (IgG)
    • 3.10.1. IgG1
    • 3.10.2. IgG2
    • 3.10.3. IgG3
    • 3.10.4. IgG4
  • 3.11. Market dynamics
    • 3.11.1. Drivers
      • 3.11.1.1. Rise in prevalence of immunodeficiency diseases
      • 3.11.1.2. Increase in adoption of immunoglobulin treatment
      • 3.11.1.3. Growth in incidence of bleeding disorders
    • 3.11.2. Restraints
      • 3.11.2.1. Stringent government regulations
      • 3.11.2.2. High cost of therapy
    • 3.11.3. Opportunities
      • 3.11.3.1. Opportunities in emerging economies
      • 3.11.3.2. Development of cost-effective therapeutics through large-scale production

CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Hypogammaglobulinemia
    • 4.2.1. Market size and forecast
  • 4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
    • 4.3.1. Market size and forecast
  • 4.4. Primary immunodeficiency diseases
    • 4.4.1. Market size and forecast
  • 4.5. Myasthenia Gravis
    • 4.5.1. Market size and forecast
  • 4.6. Multifocal motor neuropathy
    • 4.6.1. Market size and forecast
  • 4.7. Idiopathic thrombocytopenic purpura (ITP)
    • 4.7.1. Market size and forecast
  • 4.8. Inflammatory myopathies
    • 4.8.1. Market size and forecast
  • 4.9. Specific antibody deficiency
    • 4.9.1. Market size and forecast
  • 4.10. Guillain-Barre syndrome
    • 4.10.1. Market size and forecast
  • 4.11. Others
    • 4.11.1. Market size and forecast

CHAPTER 5: IMMUNOGLOBULIN MARKET, BY PRODUCT

  • 5.1. Overview
    • 5.1.1. IGG
      • 5.1.1.1. Key market trends
    • 5.1.2. Clinical interpretations
    • 5.1.3. IGA
      • 5.1.3.1. Key Market Trends
    • 5.1.4. Clinical interpretation
    • 5.1.5. IGM
      • 5.1.5.1. Key Market Trends
    • 5.1.6. Clinical interpretation
    • 5.1.7. IGE
      • 5.1.7.1. Key Market Trend
    • 5.1.8. Clinical interpretation
    • 5.1.9. IGD
      • 5.1.9.1. Key Market Trends
    • 5.1.10. Clinical interpretation

CHAPTER 6: INTRVAENOUS IMMUNOGLOBULIN MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. North America market size & forecast, by application
    • 6.2.3. North America market size & forecast, by country
      • 6.2.3.1. U.S. market size & forecast
      • 6.2.3.2. Canada market size & forecast
      • 6.2.3.3. Mexico market size & forecast
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Europe market size & forecast, by application
    • 6.3.3. Europe market size & forecast for immunoglobulin market, by country
      • 6.3.3.1. Germany market size & forecast
      • 6.3.3.2. France market size & forecast
      • 6.3.3.3. UK market size & forecast
      • 6.3.3.4. Italy market size & forecast
      • 6.3.3.5. Austria market size & forecast
      • 6.3.3.6. Russia market size & forecast
      • 6.3.3.7. Rest of Europe market size & forecast
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Asia-Pacific market size & forecast, by application
    • 6.4.3. Asia-Pacific market size & forecast, by country
      • 6.4.3.1. Australia market size & forecast
      • 6.4.3.2. China market size & forecast
      • 6.4.3.3. India market size & forecast
      • 6.4.3.4. Japan market size & forecast
      • 6.4.3.5. Rest of Asia-Pacific market size & forecast
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. LAMEA market size & forecast, by application
    • 6.5.3. LAMEA market size & forecast, by country
      • 6.5.3.1. Brazil market size & forecast
      • 6.5.3.2. Saudi Arabia market size & forecast
      • 6.5.3.3. Argentina market size & forecast
      • 6.5.3.4. Turkey market size & forecast
      • 6.5.3.5. Rest of LAMEA market size & forecast

CHAPTER 7: COMPANY PROFILES

  • 7.1. BAXTER INTERNATIONAL INC.
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Operating business segments
    • 7.1.4. Product portfolio
    • 7.1.5. Business performance
    • 7.1.6. Key strategic moves and developments
  • 7.2. BAYER AG
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Operating business segments
    • 7.2.4. Product portfolio
    • 7.2.5. Business performance
    • 7.2.6. Key strategic moves and developments
  • 7.3. BIOTEST AG
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Operating business segments
    • 7.3.4. Product portfolio
    • 7.3.5. Business performance
  • 7.4. CHINA BIOLOGIC PRODUCTS, INC.
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Operating business segments
    • 7.4.4. Product portfolio
    • 7.4.5. Business performance
  • 7.5. CSL LIMITED
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
    • 7.5.3. Operating business segments
    • 7.5.4. Product portfolio
    • 7.5.5. Business performance
  • 7.6. GRIFOLS S.A.
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
    • 7.6.3. Operating business segments
    • 7.6.4. Product portfolio
    • 7.6.5. Business performance
    • 7.6.6. Key strategic moves and developments
  • 7.7. KEDRION BIOPHARMA INC.
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Operating business segments
    • 7.7.4. Product portfolio
    • 7.7.5. Business performance
    • 7.7.6. Key strategic moves and developments
  • 7.8. LFB SA (LFB BIOTECHNOLOGIES SAS)
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Operating business segments
    • 7.8.4. Product portfolio
    • 7.8.5. Business performance
  • 7.9. OCTAPHARMA AG
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
    • 7.9.3. Operating business segments
    • 7.9.4. Product portfolio
    • 7.9.5. Business performance
  • 7.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Operating business segments
    • 7.10.4. Product portfolio
    • 7.10.5. Business performance
    • 7.10.6. Key strategic moves and developments

List of Tables

  • TABLE 01. COMMERCIALIZED IMMUNOGLOBULIN PRODUCTS
  • TABLE 02. U.S. FDA INDICATIONS FOR IMMUNOGLOBULIN
  • TABLE 03. EMA-APPROVED INDICATIONS FOR IMMUNOGLOBULIN
  • TABLE 04. IGG SUBCLASS
  • TABLE 05. FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS
  • TABLE 06. DISEASES ASSOCIATED WITH IGG SUBCLASS DEFICIENCY
  • TABLE 07. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
  • TABLE 08. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAM)
  • TABLE 09. COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS
  • TABLE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 20172025 ($MILLION)
  • TABLE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 20172025 (KILOGRAMS)
  • TABLE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR CIDP, BY REGION, 20172025 ($MILLION)
  • TABLE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR CIPD, BY REGION, 20172025 (KILOGRAMS)
  • TABLE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR PRIMARY IMMUNODEFICIENCY DISEASES BY REGION, 20172025 ($MILLION)
  • TABLE 15. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR PRIMARY IMMUNODEFICIENCY DISEASES BY REGION, 20172025 (KILOGRAMS)
  • TABLE 16. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 20172025 ($MILLION)
  • TABLE 17. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 20172025 (KILOGRAMS)
  • TABLE 18. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 20172025 ($MILLION)
  • TABLE 19. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 20172025 (KILOGRAMS)
  • TABLE 20. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION, 20172025 ($MILLION)
  • TABLE 21. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION, 20172025 (KILOGRAMS)
  • TABLE 22. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION, 20172025 ($MILLION)
  • TABLE 23. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION, 20172025 (KILOGRAMS)
  • TABLE 24. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION, 20172025 ($MILLION)
  • TABLE 25. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION, 20172025 (KILOGRAMS)
  • TABLE 26. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME, BY REGION, 20172025 ($MILLION)
  • TABLE 27. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME), BY REGION, 20172025 (KILOGRAMS)
  • TABLE 28. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 20172025 ($MILLION)
  • TABLE 29. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 20172025 (KILOGRAMS)
  • TABLE 30. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, 20172025 ($MILLION)
  • TABLE 31. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, 2017-2025 (KILOGRAMS))
  • TABLE 32. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
  • TABLE 33. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAMS)
  • TABLE 34. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 ($MILLION)
  • TABLE 35. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (KILOGRAMS)
  • TABLE 36. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
  • TABLE 37. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAMS)
  • TABLE 38. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 ($MILLION)
  • TABLE 39. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (KILOGRAMS)
  • TABLE 40. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
  • TABLE 41. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAMS)
  • TABLE 42. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • TABLE 43. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (KILOGRAMS)
  • TABLE 44. LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
  • TABLE 45. LAMEA IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAMS)
  • TABLE 46. LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 ($MILLION)
  • TABLE 47. LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (KILOGRAMS)
  • TABLE 48. BAXTER: COMPANY SNAPSHOT
  • TABLE 49. BAXTER: OPERATING SEGMENTS
  • TABLE 50. BAXTER: PRODUCT PORTFOLIO
  • TABLE 51. BAYER: COMPANY SNAPSHOT
  • TABLE 52. BAYER: OPERATING SEGMENTS
  • TABLE 53. BAXTER: PRODUCT PORTFOLIO
  • TABLE 54. BIOTEST: COMPANY SNAPSHOT
  • TABLE 55. BIOTEST: OPERATING SEGMENTS
  • TABLE 56. BIOTEST: OPERATING SEGMENT
  • TABLE 57. CHINA BIOLOGIC COMPANY SNAPSHOT
  • TABLE 58. CHINA BIOLOGIC PRODUCT PORTFOLIO
  • TABLE 59. CSL: COMPANY SNAPSHOT
  • TABLE 60. CSL: PRODUCT SEGMENTS
  • TABLE 61. CSL: PRODUCT PORTFOLIO
  • TABLE 62. GRIFOLS: COMPANY SNAPSHOT
  • TABLE 63. GRIFOLS: OPERATING SEGMENTS
  • TABLE 64. GRIFOLS: PRODUCT PORTFOLIO
  • TABLE 65. KEDRION: COMPANY SNAPSHOT
  • TABLE 66. KEDRION: PRODUCT PORTFOLIO
  • TABLE 67. LFB: COMPANY SNAPSHOT
  • TABLE 68. LFB: PRODUCT SEGMENTS
  • TABLE 69. LFB: PRODUCT PORTFOLIO
  • TABLE 70. OCTAPHARMA: COMPANY SNAPSHOT
  • TABLE 71. OCTAPHARMA: PRODUCT SEGMENTS
  • TABLE 72. OCTAPHARMA: PRODUCT PORTFOLIO
  • TABLE 73. TAKEDA: COMPANY SNAPSHOT
  • TABLE 74. TAKEDA: PRODUCT PORTFOLIO

List of Figures

  • FIGURE 01. INTRAVENOUS IMMUNOGLOBULIN MARKET SEGMENTATION
  • FIGURE 02. TOP INVESTMENT POCKETS
  • FIGURE 03. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 04. LOW BARGAINING POWER OF BUYERS
  • FIGURE 05. LOW THREAT OF SUBSTITUTION
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERTAE COMPETITIVE RIVALRY
  • FIGURE 08. VALUE CHAIN ANALYSIS
  • FIGURE 09. MARKET SHARE ANALYSIS, 2017
  • FIGURE 10. GLOBAL IMMUNOGLOBULIN MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 11. U.S. INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 12. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 13. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 14. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 15. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 16. UK INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 17. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 18. AUSTRIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 19. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • REST OF EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 20. AUSTRALIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 21. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 22. INDIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 23. JAPAN INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 24. REST OF ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 25. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 26. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 27. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 28. TURKEY INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 29. REST OF LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE ($MILLION) AND VOLUME (KILOGRAMS), 2017-2025
  • FIGURE 30. BAXTER: NET SALES, 20152017 ($MILLION)
  • FIGURE 31. BAXTER: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 32. BAYER: NET SALES, 20152017 ($MILLION)
  • FIGURE 33. BAYER: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 34. BAYER: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 35. BIOTEST: NET SALES, 20152017 ($MILLION)
  • FIGURE 36. BIOTEST: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 37. BIOTEST: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 38. CHINA BIOLOGIC NET SALES, 20152017 ($MILLION)
  • FIGURE 39. CSL: NET SALES, 20152017 ($MILLION)
  • FIGURE 40. CSL: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 41. CSL: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 42. GRIFOLS: NET SALES, 20152017 ($MILLION)
  • FIGURE 43. GRIFOLS: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 44. GRIFOLS: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 45. KEDRION: NET SALES, 20152017 ($MILLION)
  • FIGURE 46. KEDRION: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 47. LFB: NET SALES, 20142016 ($MILLION)
  • FIGURE 48. LFB: REVENUE SHARE BY PRODUCT SEGMENT, 2016 (%)
  • FIGURE 49. LFB: REVENUE SHARE BY REGION, 2016 (%)
  • FIGURE 50. OCTAPHARMA: NET SALES, 20152017 ($MILLION)
  • FIGURE 51. TAKEDA: NET SALES, 20152017 ($MILLION)
  • FIGURE 52. TAKEDA: REVENUE SHARE BY REGION, 2017 (%)